Tumor evasion mechanisms and poor patient response rates limit the efficacy of standard immunotherapy. Overcoming these inhibitory pathways restores anti-tumor immune activity.

The enzymatic activity of IL4I1 catabolizes essential amino acids to produce metabolites that inhibit T-cell activation and promote immune evasion. Neutralizing this metabolic pathway prevents the biochemical silencing of the host immune response within the tumor site.

Off-target toxicity and poor localization of therapeutic agents to specific cancer cells. Enhancing selectivity prevents systemic side effects and increases the therapeutic window.

Interleukin-2 suffers from rapid renal clearance and poor metabolic stability. Extending circulation time reduces dosing frequency and improves therapeutic window.